2,932 Elevance Health, Inc. $ELV Shares Acquired by Chicago Partners Investment Group LLC

Posted by Brenda Bartman on Nov 7th, 2026

Chicago Partners Investment Group LLC lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 119.9% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 5,377 shares of the company’s stock after buying an additional 2,932 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Elevance Health were worth $2,366,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of ELV. Compass Financial Management LLC grew its stake in Elevance Health by 15.6% in the 3rd quarter. Compass Financial Management LLC now owns 349 shares of the company’s stock worth $136,000 after acquiring an additional 47 shares during the period. Pzena Investment Management LLC lifted its stake in shares of Elevance Health by 3.8% in the third quarter. Pzena Investment Management LLC now owns 233,128 shares of the company’s stock worth $90,645,000 after acquiring an additional 8,553 shares in the last quarter. Rakuten Investment Management Inc. acquired a new position in Elevance Health during the 3rd quarter worth $15,287,000. Provenance Wealth Advisors LLC acquired a new stake in shares of Elevance Health during the 3rd quarter valued at approximately $105,000. Finally, Gerber Kawasaki Wealth & Investment Management boosted its stake in Elevance Health by 24.7% in the third quarter. Gerber Kawasaki Wealth & Investment Management now owns 895 shares of the company’s stock valued at $348,000 after acquiring an additional 177 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ELV. TD Cowen boosted their target price on Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Leerink Partners increased their price target on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Mizuho set a $490.00 price objective on Elevance Health in a research note on Friday, October 23rd. Barclays upped their price objective on shares of Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, Wells Fargo & Company raised their price objective on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a report on Tuesday, October 27th. Fifteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $456.48.

Check Out Our Latest Stock Report on ELV

Elevance Health Stock Down 1.4%

Shares of NYSE:ELV traded down $5.83 during trading on Friday, hitting $426.17. 1,443,875 shares of the company’s stock traded hands, compared to its average volume of 1,442,885. The company has a market cap of $92.08 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 1.97 and a beta of 0.63. The company has a 50-day moving average price of $412.92 and a 200-day moving average price of $373.58. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $450.69. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV – Get Free Report) last released its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter last year, the firm earned $6.03 earnings per share. As a group, research analysts forecast that Elevance Health, Inc. will post 29.16 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio is 29.34%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ratnakar Lavu sold 1,300 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president directly owned 14,849 shares in the company, valued at approximately $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.34% of the stock is currently owned by company insiders.

About Elevance Health

(Free Report)

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.